Prne
May 29th, 2009
MADRID - Phase 3 study has demonstrated that Induction Chemotherapy prior to ChemoRadiotherapy significantly increased time-to-treatment failure in comparison to standard ChemoRadiotherapy alone -
The Spanish Head and Neck Cancer Cooperative Group (TTCC) announced today that Induction Chemotherapy (IC) delivered prior to standard ChemoRadiotherapy (CRT), a treatment paradigm defined as sequential therapy, compared to upfront CRT alone, significantly prolonged Time-to-Treatment Failure (TTF) for patients with unresectable Locally Advanced Head and Neck Cancer (LAHNC). The endpoint of Time-to-Treatment Failure was defined as a composite of time-to-disease progression, -to-surgery or other cancer-related treatments, -to-drop-out due to an adverse event, and to death from any cause.
Final results (abstract #6009) from the Phase 3 randomized study were presented by Prof. Ricardo Hitt, of the University Hospital 12 de Octubre, Madrid, in an oral presentation at the 2009 annual meeting of the American Society of Clinical Oncology (ASCO). The results of this study have also been selected for inclusion in the Best of ASCO(R) program. The Best of ASCO(R) is an educational initiative that condenses highlights from ASCO’s Annual Meeting, with the objective of increasing global access to cutting-edge science that is relevant and significant in oncology today.
This study enrolled 439 patients with Locally Advanced Head and Neck Cancer with good performance status, who were randomly assigned to receive standard CRT (cisplatin and fractionated radiation) versus the same treatment preceded by IC, which consisted of cisplatin plus 5-fluorouracil (5-FU) with or without Taxotere(R) (docetaxel) Injection Concentrate. The study was designed to compare the results of those patients who received IC prior to CRT (sequential therapy) and patients who received CRT alone.
The sequential therapy of adding IC to CRT improved Time-to-Treatment Failure (TTF) from 5.0 months to 12.5 months (p< 0.0001), a 7.5 month increase. Furthermore, a secondary endpoint of loco-regional control, was observed in 61.5% of the patients treated with the sequential strategy (IC+CRT) compared to 44.5% of those patients treated with CRT alone (p=0.002).
The most frequent severe (grade 3-4) adverse reactions were stomatitis (44% for IC+CRT vs. 31% for CRT) and febrile neutropenia (10% for IC+CRT vs. 1% for CRT). Other adverse events included neutropenia and asthenia.
“These study results illustrate that this complex disease deserves a rational and comprehensive management strategy to overcome its pathologic mechanism and the inherent possibility of failure of clinical control,” said Prof. Ricardo Hitt, MD, PhD, the study principal investigator, from Medical Oncology Service of the University Hospital 12 de Octubre, Madrid, Spain.
Every year more than 640,000 people worldwide are diagnosed with head and neck cancer, and an estimated more than 350,000 will die from the disease. Head and neck cancer is a group of tumors that mostly arise in the cells that line the mucosal surfaces, giving rise to squamous cell carcinoma in the head and neck area, such as the mouth, tongue, tonsils, voice box and throat.
“This trial showed that adding Induction Chemotherapy to ChemoRadiotherapy increased failure-free survival while significantly increasing local control in patients with advanced unresectable head and neck cancer,” said Fadlo Khuri, MD, Professor and Roberto Goizueta Chair of Hematology and Medical Oncology at Emory University, Atlanta, GA, USA. Dr. Khuri, a renowned head and neck cancer expert, also added: “These data may help define and clarify standard approaches to the treatment of patients with advanced unresectable disease.”
About the Spanish Head and Neck Cancer Cooperative Group, TTCC
Grupo Espanol de Tratamiento de Tumores de Cabeza y Cuello (TTCC) is a Spanish non-profit scientific cooperative group fully devoted to head and neck cancer. The group is comprised of medical oncologists, who belong to the Spanish Society of Medical Oncology (SEOM) as well as of other health professionals related to head and neck cancer research and treatment. The main Spanish Head and Neck Cancer Cooperative Group objectives are to promote basic, epidemiological and clinical research, and to provide education to doctors and patients and dissemination of information in the field of head and neck cancer to the Spanish general population.
Contact TTCC: Pr. Ricardo Hitt: +34-629-26-28-33 Tara Dimilia: +1-908-884-7024
Source: Spanish Head and Neck Cancer Cooperative Group
Professor Ricardo Hitt, +34-629-26-28-33, or Tara Dimilia, +1-908-884-7024, both for Spanish Head and Neck Cancer Cooperative Group
Filed under Biotechnology, Business, Clinical Trials / Medical Discoveries, Government and Policy, Health, Health Care / Hospitals, Hispanic Oriented, Medical Equipment, Multicultural, Not For Profit, Pharmaceuticals, Surveys / Polls / Research, Trade Show | Tags: Madrid, Scandinavia, Spanish Head and Neck Cancer Cooperative Group, Western Europe | Comment Below
Related Press Releases Afinitor(R) (everolimus) Now Licensed in UK for Advanced Kidney Cancer Patients After Failure of First Line Vascular Targeted Therapy (1,2)September 23rd, 2009 FRIMLEY, England -
- This Press Release is Intended for Consumer Media Only
- Afinitor More Than Doubles the Median Time Without Tumour Growth and Reduces the Risk of Disease Worsening or Death by 67% Compared With Placebo (2)
- Patients With Advanced Kidney Cancer Have Limited Options Once Tumours Progress After First Line Standard Therapy(3)
- Recently Published UK Expert Clinical Consensus Recommend Afinitor as Second-Line Therapy for Advanced Kidney Cancer Based on Class I Evidence(4)
Afinitor(R) (everolimus) has recently been licensed for the treatment of advanced kidney cancer after failure of treatments which prevent the growth of the tumour's blood vessels. The growth of the blood vessels are essential for the cancer to survive.(1) The European Commission (EC) approved everolimus for this use on 3rd August 2009.(1)
Prior to this date, there were no licensed treatment options for advanced kidney cancer patients whose cancer progressed while on or after treatment with these targeted therapies. Capecitabine Added to Standard Treatment Given Before Surgery Helps to Eradicate Tumours in Patients With Early Breast CancerSeptember 22nd, 2009 BERLIN -
- The Austrian Breast and Colorectal Cancer Study Group Present Data Which Highlight Benefits of Adding capecitabine to epirubicin and docetaxel in the Neoadjuvant Setting
Data from the ABCSG-24 study presented today at the joint 15th ECCO and 34th ESMO congress in Berlin, Germany, show that adding capecitabine (Xeloda(R)) to anthracycline- and taxane-containing regimens prior to surgery (neoadjuvant therapy) completely eradicated the tumour in 24% of women with HER2-positive or HER2-negative early breast cancer. This is an impressive finding since the proportion of women achieving total tumour eradication with standard chemotherapy[*] for HER2-positive or HER2-negative early breast cancer is less than 20% (range 6-18%).[1]
"These new data show that adding capecitabine to epirubicin and docetaxel neoadjuvant regimens when treating women with early breast cancer, results in increased efficacy compared to epirubicin and docetaxel alone. British Woman Celebrates a Year of Living Cancer-FreeJuly 30th, 2009 LONDON -
It's been a year since fashion designer Joanne Scott went through a cancer treatment that changed her life -- and made history to boot. Ms Scott, 54, was the first person in the world to receive an injection of tumour-activated natural killer (TaNK) cells as a treatment for leukaemia. Positive CHMP Opinion for JAVLOR(R) in Metastatic Treatment of Bladder Cancer After Failure of a Prior Platinum-Containing RegimenJune 25th, 2009 CASTRES, France - Laboratoires Pierre Fabre announce today that the Committee for Medicinal Products for Human Use (CHMP), the scientific advisory committee of the European Medicines Agency (EMEA), has issued a positive opinion supporting approval and is recommending to grant marketing authorisation for JAVLOR(R) as monotherapy in metastatic treatment of bladder cancer (advanced or metastatic transitional cell carcinoma of the urothelial tract after failure of a prior platinum-containing regimen). CHMP has issued a positive opinion based on two phase II study results and on the only phase III randomized study ever conducted in the indication of metastatic treatment of bladder cancer after failure of a prior platinum-containing regimen. Second Generation 5-HT3 Antagonists Open New Perspectives in Emesis PreventionJune 24th, 2009 ROME - The MASCC (Multinational Association of Supportive Care in Cancer) 2009 International Symposium opens today in Rome, Italy - Chemotherapy-induced nausea and vomiting (CINV), treatment of pain, and quality of life in survivors among the key topics of the conference
"Supportive care in cancer is a field of increasing relevance for both oncology patients and clinical research", said Maurizio Tonato, Co-chair of the MASCC 2009 International Symposium, inaugurated in Rome today. Tonato explained how supportive care, in conjunction with anticancer treatments, may significantly increase quality of life in patients especially addressing the most dreaded consequences and complications, including pain and emesis. Bone Cancer Research Trust Calls for New Treatments for Bone CancerJune 17th, 2009 LONDON - The Bone Cancer Research Trust is calling for new treatments for bone cancers affecting children and young people. This includes osteosarcoma and Ewing's sarcoma, the two most common forms of primary bone cancer. Single Dose Palonosetron Prevents Emesis Induced by Chemotherapy in Non Hodgkin's Lymphoma PatientsJune 4th, 2009 BERLIN, Germany - Single Dose Palonosetron is Effective and Safe in Preventing Chemotherapy-Induced Nausea and Vomiting (CINV) in Patients With Aggressive Non-Hodgkin's Lymphomas who Undergo Moderately Emetogenic Chemotherapy
- Data Presented Today at the European Haematology Association Congress in Berlin, Germany
New data presented today at the EHA (European Haematology Association) Congress in Berlin show that a single dose of palonosetron, a second generation 5-HT3 receptor antagonist, is effective and safe in preventing chemotherapy-induced nausea and vomiting (CINV) in patients with aggressive non Hodgkin's lymphoma (NHL), treated with cytotoxic agents. The result comes from a study conducted in Italy on behalf of the Italian Group of Study on Lymphomas (GISL) by a multicentric team coordinated by Dr. Randomized Controlled Trial of Radioactive Resin Microspheres Demonstrates Significant Delay in Progression of Disease in Patients With Colorectal Cancer Liver Metastases who Have Exhausted ChemotherapyMay 31st, 2009 ORLANDO, Florida - The time to progression of disease in patients with colorectal cancer liver metastases who have exhausted all chemotherapy options can be more than doubled through the use of radioactive resin microspheres, according to the results of a prospective randomized controlled trial presented at the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO).[1] The multicenter phase III study compared the use of 5-fluorouracil (5FU) alone to 5FU plus 90Y resin microspheres (SIR-Spheres; Sirtex Medical, Sydney) and was conducted by a collaboration of university hospitals in Belgium. "Patients with colorectal cancer liver metastases who are resistant or intolerant of chemotherapy should be considered for salvage therapy using 90Y resin microspheres combined with 5FU-based chemotherapy," said Dr Alain Hendlisz, Head of Digestive Oncology and Gastroenterology at Institut Jules Bordet Université Libre de Bruxelles, Brussels, Belgium, and principal investigator of the study. Successful Phase I/II Clinical Trial Results From Cancer Patients Treated With Anti-Cancer Drug From Axelar ABMay 5th, 2009 STOCKHOLM - Axelar AB today announced successful completion of the single-day oral dosing part of its ongoing phase I/II clinical trial on cancer patients with its new anti-cancer drug AXL1717,an insulin-like growth factor-1 (IGF-1) receptor inhibitor which has no effects on the closely related insulin receptor. The study is conducted in Sweden on patients having terminal cancer disease. Palonosetron Warrants Adequate Caloric Intake in Oncology Patients Receiving High Emetogenic ChemotherapyMarch 19th, 2009 ZURICH, Switzerland - A new, innovative study shows that a single dose of palonosetron, the
second generation 5-HT3 antagonist, plus dexamethasone not only prevents
chemotherapy-induced nausea and vomiting (CINV), but also allows adequate
caloric intake in oncology patients. Data presented today at the ESMO
Symposium on Cancer and Nutrition in Zurich, Switzerland
New data presented today at the ESMO (European Society of Medical
Oncology) Symposium on Cancer and Nutrition in Zurich shows that
palonosetron, a second generation 5-HT3 receptor antagonist, warrants
adequate caloric intake in oncology patients receiving high emetogenic
chemotherapy (HEC).
Related News Experimental drug shows promise in treating head, neck cancersApril 29th, 2009 WASHINGTON - An anti-cancer compound studied for treating blood cancers may also help in treating cancers of the head and neck, say researchers at Albert Einstein College of Medicine of Yeshiva University. The study involved a new class of chemotherapy agents known as histone deacetylase (HDAC) inhibitors, which affect the availability of genes that are transcribed and translated into proteins. 60-year-old drug may help treat deadly cancersAugust 27th, 2009 WASHINGTON - A drug developed back in 1940s has a potential to treat some of the most deadly cancers, it has emerged. Scientists from Institute of Cancer Research in London have discovered that methotrexate, a chemotherapy treatment invented in the 1940s, has the potential to work against a genetic fault called HNPCC. My doctor says I'll lose my hair soon: Jade GoodyDecember 29th, 2008 LONDON - Reality show star Jade Goody has revealed that her doctor has told her that she will be bald in a few weeks. Goody, who is undergoing treatment for cervical cancer, will lose her hair by Jan 8 after chemotherapy. 'Frail' cancer-stricken Patrick Swayze continues 60-a-day cigarette habitMarch 14th, 2009 LONDON - Cancer-stricken American actor Patrick Swayze, who has become very frail and thin and suffered hair loss due to chemotherapy, was recently seen lighting a cigarette during a shopping trip in LA. Swayze, 56, who was slightly limping as he walked, was with his wife Lisa Niemi, 52, and a male friend. Judge: Teen with cancer who fled Minn. must continue chemotherapy, treatment appears workingJune 24th, 2009 Minn. judge orders teen to continue chemotherapyNEW ULM, Minn. — A 13-year-old boy with cancer who fled Minnesota last month to avoid chemotherapy must continue getting the treatment because it appears to be working, a judge ruled Tuesday. Cancer survivor Specter talks chemo, kicks off speculation about health; aide says all wellJuly 28th, 2009 Specter: No chemo in more than a yearWASHINGTON — Sen. Arlen Specter ignited a new round of speculation about his health when he remarked that his eyes and nose were running as a side effect of chemotherapy. Review uncovers 6 more cases of botched cancer treatments at VA in PhiladelphiaAugust 18th, 2009 6 more cases of botched cancer treatment at Pa. VAPHILADELPHIA — Six more cases have been found of cancer patients being given incorrect radiation doses at the Veterans Affairs Medical Center in Philadelphia. Natalie Cole undergoes chemotherapy in dressing roomApril 15th, 2009 WASHINGTON - Renowned vocalist Natalie Cole, who is known for her utter professionalism, decided to undergo chemotherapy treatment in her concert dressing room, in a bid to continue performing. Cole, who is battling with Hepatitis C, did not check into a hospital to get treated because she did not want to take time off from work. "LET US JOIN HANDS TO FIGHT CANCER"June 22nd, 2009 COMMEMORATING AN OCTA- OCCASION OF ACHIEVEMENT!
Cancer Aid and Research Foundation (CARF) commemorated their 8th foundation Day on 20 June 2009 at Shanmukhanand Hall, Sion, Mumbai. The event was held from 5 pm onwards, wherein the Foundation distributed cheques of Rs. Chronic diseases linked to higher levels of depressionJanuary 15th, 2009 WASHINGTON - People with chronic obstructive pulmonary disease (COPD) are nearly twice as likely to be depressed as diabetics. Dutch researchers compared the health characteristics of 999 patients with COPD, 978 patients with diabetes, and 2,494 healthy control subjects.
|
|
